Qian-Yun Cai1,2, Zhong-Jie Zhou3, Rong Luo1,2, Jing Gan2, Shi-Ping Li2, De-Zhi Mu1,2, Chao-Min Wan4,5,6. 1. Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China. 2. Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China. 3. Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China. 4. Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China. wcm0220@sina.com. 5. Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China. wcm0220@sina.com. 6. Department of Pediatrics, West China Second University Hospital, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, 610041, China. wcm0220@sina.com.
Abstract
BACKGROUND: To review the available evidence from prospective studies on the safety and tolerability of the ketogenic diet (KD) for the treatment of refractory childhood epilepsy. METHODS: A comprehensive bibliographic search was performed with the aim of retrieving prospective studies that monitored adverse effects (AEs) in children after receiving the classic or medium-chain triglyceride KD therapy for refractory epilepsy. RESULTS: A total of 45 studies were retrieved, including 7 randomized controlled trials. More than 40 categories of AEs were reported. The most common AEs included gastrointestinal disturbances (40.6%), hyperlipidemia (12.8%), hyperuricemia (4.4%), lethargy (4.1%), infectious diseases (3.8%) and hypoproteinemia (3.8%). Severe AEs, such as respiratory failure and pancreatitis, occurred in no more than 0.5% of children. Specifically, patients receiving KD therapy should be monitored for osteopenia, urological stones, right ventricular diastolic dysfunction, and growth disturbance. The total retention rates of the diet for 1 year and 2 years were 45.7% and 29.2%, respectively. Nearly half of the patients discontinued the diet because of lack of efficacy. AEs were not the main reason for the KD discontinuation. None of the 24 deaths reported after initiation of the diet was attributed to the KD. CONCLUSIONS: KD is a relatively safe dietary therapy. However, because the KD can cause various AEs, it should be implemented under careful medical supervision. Continuous follow-up is needed to address the long-term impact of the diet on the overall health of children.
BACKGROUND: To review the available evidence from prospective studies on the safety and tolerability of the ketogenic diet (KD) for the treatment of refractory childhood epilepsy. METHODS: A comprehensive bibliographic search was performed with the aim of retrieving prospective studies that monitored adverse effects (AEs) in children after receiving the classic or medium-chain triglyceride KD therapy for refractory epilepsy. RESULTS: A total of 45 studies were retrieved, including 7 randomized controlled trials. More than 40 categories of AEs were reported. The most common AEs included gastrointestinal disturbances (40.6%), hyperlipidemia (12.8%), hyperuricemia (4.4%), lethargy (4.1%), infectious diseases (3.8%) and hypoproteinemia (3.8%). Severe AEs, such as respiratory failure and pancreatitis, occurred in no more than 0.5% of children. Specifically, patients receiving KD therapy should be monitored for osteopenia, urological stones, right ventricular diastolic dysfunction, and growth disturbance. The total retention rates of the diet for 1 year and 2 years were 45.7% and 29.2%, respectively. Nearly half of the patients discontinued the diet because of lack of efficacy. AEs were not the main reason for the KD discontinuation. None of the 24 deaths reported after initiation of the diet was attributed to the KD. CONCLUSIONS: KD is a relatively safe dietary therapy. However, because the KD can cause various AEs, it should be implemented under careful medical supervision. Continuous follow-up is needed to address the long-term impact of the diet on the overall health of children.
Authors: S L Furth; J C Casey; P L Pyzik; A M Neu; S G Docimo; E P Vining; J M Freeman; B A Fivush Journal: Pediatr Nephrol Date: 2000-11 Impact factor: 3.714
Authors: A G Christina Bergqvist; Joan I Schall; Paul R Gallagher; Avital Cnaan; Virginia A Stallings Journal: Epilepsia Date: 2005-11 Impact factor: 5.864
Authors: Danielle A J E Lambrechts; Reina J A de Kinderen; Hans S H Vles; Anton J de Louw; Albert P Aldenkamp; Marian J M Majoie Journal: Epilepsy Behav Date: 2015-08-24 Impact factor: 2.937
Authors: Brianna J Stubbs; Pete J Cox; Rhys D Evans; Peter Santer; Jack J Miller; Olivia K Faull; Snapper Magor-Elliott; Satoshi Hiyama; Matthew Stirling; Kieran Clarke Journal: Front Physiol Date: 2017-10-30 Impact factor: 4.566
Authors: Gerwyn Morris; Basant K Puri; Andre Carvalho; Michael Maes; Michael Berk; Anu Ruusunen; Lisa Olive Journal: Int J Neuropsychopharmacol Date: 2020-06-24 Impact factor: 5.176